化疗是目前临床癌症治疗最有效的方法之一。然而化疗耐药是导致化疗疗效和预后不良的重要原因，已成为肿瘤化疗领域亟待解决的问题。因此，深入研究分析癌症化疗耐药的机制及其调控因素非常重要。长非编码 RNA 核副斑组装转录本 1 (LncRNA NEAT1) 已被证明与癌症的化疗耐药性密切相关。 NEAT1通过调节细胞凋亡、细胞周期、药物转运和代谢、DNA损伤修复、EMT、自噬、癌症干细胞特征和代谢重编程来诱导癌细胞对化疗药物的耐药性。这表明NEAT1可能是克服化疗耐药的重要靶点，并有望成为预测化疗效果的潜在生物标志物。本文总结了NEAT1在不同癌症中的表达特点及临床特点，深入探讨了NEAT1在癌症化疗耐药中的调控作用及相关分子机制，旨在阐明NEAT1作为克服癌症化疗耐药的新靶点及化疗的可行性敏化剂，以期为未来克服癌症耐药困境提供潜在的治疗方向。© 2024。作者。

Chemotherapy is currently one of the most effective methods in clinical cancer treatment. However, chemotherapy resistance is an important reason for poor chemotherapy efficacy and prognosis, which has become an urgent problem to be solved in the field of cancer chemotherapy. Therefore, it is very important to deeply study and analyze the mechanism of cancer chemotherapy resistance and its regulatory factors. Long non-coding RNA nuclear paraspeckle assembly transcript 1 (LncRNA NEAT1) has been shown to be closely associated with chemotherapy resistance in cancer. NEAT1 induces cancer cell resistance to chemotherapeutic drugs by regulating cell apoptosis, cell cycle, drug transport and metabolism, DNA damage repair, EMT, autophagy, cancer stem cell characteristics, and metabolic reprogramming. This indicates that NEAT1 may be an important target to overcome chemotherapy resistance and is expected to be a potential biomarker to predict the effect of chemotherapy. This article summarizes the expression characteristics and clinical characteristics of NEAT1 in different cancers, and deeply discusses the regulatory role of NEAT1 in cancer chemotherapy resistance and related molecular mechanisms, aiming to clarify NEAT1 as a new target to overcome cancer chemotherapy resistance and the feasibility of chemotherapy sensitizers, with a view to providing a potential therapeutic direction for overcoming the dilemma of cancer resistance in the future.© 2024. The Author(s).